Efficacy of single versus four repeated doses of praziquantel against Schistosoma mansoni infection in school-aged children from Côte d'Ivoire based on Kato-Katz and POC-CCA: An open-label, randomised controlled trial (RePST).

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101291488 Publication Model: eCollection Cited Medium: Internet ISSN: 1935-2735 (Electronic) Linking ISSN: 19352727 NLM ISO Abbreviation: PLoS Negl Trop Dis Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

Anthelmintics/*administration & dosage ; Antigens, Helminth/*urine ; Drug Monitoring/*methods ; Glycoproteins/*urine ; Helminth Proteins/*urine ; Parasitology/*methods ; Praziquantel/*administration & dosage ; Schistosoma mansoni/*isolation & purification ; Schistosomiasis mansoni/*drug therapy; Adolescent ; Animals ; Chemoprevention/methods ; Child ; Child, Preschool ; Cote d'Ivoire ; Female ; Humans ; Male ; Schistosomiasis mansoni/prevention & control ; Schools ; Treatment Outcome ; Urine/parasitology

Background: Preventive chemotherapy with praziquantel (PZQ) is the cornerstone of schistosomiasis control. However, a single dose of PZQ (40 mg/kg) does not cure all infections. Repeated doses of PZQ at short intervals might increase efficacy in terms of cure rate (CR) and intensity reduction rate (IRR). Here, we determined the efficacy of a single versus four repeated treatments with PZQ on Schistosoma mansoni infection in school-aged children from Côte d'Ivoire, using two different diagnostic tests.
Methods: An open-label, randomized controlled trial was conducted from October 2018 to January 2019. School-aged children with a confirmed S. mansoni infection based on Kato-Katz (KK) and point-of-care circulating cathodic antigen (POC-CCA) urine cassette test were randomly assigned to receive either a single or four repeated doses of PZQ, administered at two-week intervals. The primary outcome was the difference in CR between the two treatment arms, measured by triplicate KK thick smears 10 weeks after the first treatment. Secondary outcomes included CR estimated by POC-CCA, IRR by KK and POC-CCA, and safety of repeated PZQ administration.
Principal Findings: During baseline screening, 1,022 children were assessed for eligibility of whom 153 (15%) had a detectable S. mansoni infection, and hence, were randomized to the standard treatment group (N = 70) and the intense treatment group (N = 83). Based on KK, the CR was 42% (95% confidence interval (CI) 31-52%) in the standard treatment group and 86% (95% CI 75-92%) in the intense treatment group. Observed IRR was 72% (95% CI 55-83%) in the standard treatment group and 95% (95% CI 85-98%) in the intense treatment group. The CR estimated by POC-CCA was 18% (95% CI 11-27%) and 36% (95% CI 26-46%) in the standard and intense treatment group, respectively. Repeated PZQ treatment did not result in a higher number of adverse events.
Conclusion/significance: The observed CR using KK was significantly higher after four repeated treatments compared to a single treatment, without an increase in adverse events. Using POC-CCA, the observed CR was significantly lower than measured by KK, indicating that PZQ may be considerably less efficacious as concluded by KK. Our findings highlight the need for reliable and more accurate diagnostic tools, which are essential for monitoring treatment efficacy, identifying changes in transmission, and accurately quantifying the intensity of infection in distinct populations. In addition, the higher CR in the intense treatment group suggests that more focused and intense PZQ treatment can help to advance schistosomiasis control.
Trial Registration: www.clinicaltrials.gov NCT02868385.
Competing Interests: The authors have declared that no competing interests exist.

Clin Microbiol Infect. 2015 Jun;21(6):529-42. (PMID: 25843503)
PLoS Negl Trop Dis. 2017 Nov 13;11(11):e0006054. (PMID: 29131820)
PLoS Comput Biol. 2013;9(12):e1003402. (PMID: 24367250)
PLoS Negl Trop Dis. 2011 Sep;5(9):e1321. (PMID: 21949893)
PLoS Negl Trop Dis. 2015 May 26;9(5):e0003796. (PMID: 26011733)
PLoS Negl Trop Dis. 2014 Jul 24;8(7):e2865. (PMID: 25058013)
Parasit Vectors. 2017 Jan 26;10(1):47. (PMID: 28126024)
Lancet. 2005 Apr 30-May 6;365(9470):1561-9. (PMID: 15866310)
Clin Infect Dis. 2010 May 1;50(9):1205-13. (PMID: 20350194)
Trop Med Int Health. 2001 Oct;6(10):817-25. (PMID: 11679130)
PLoS Negl Trop Dis. 2018 Jun 28;12(6):e0006484. (PMID: 29953454)
J Biomed Inform. 2009 Apr;42(2):377-81. (PMID: 18929686)
PLoS Negl Trop Dis. 2015 Jun 18;9(6):e0003821. (PMID: 26086551)
Parasit Vectors. 2016 Jan 27;9:41. (PMID: 26813154)
Trends Parasitol. 2014 Nov;30(11):528-37. (PMID: 25217844)
PLoS Negl Trop Dis. 2015 Jul 28;9(7):e0003959. (PMID: 26217948)
Int J Parasitol. 2006 Oct;36(12):1241-4. (PMID: 16930605)
Rev Inst Med Trop Sao Paulo. 1972 Nov-Dec;14(6):397-400. (PMID: 4675644)
J Parasitol. 1996 Aug;82(4):557-64. (PMID: 8691363)
Infect Dis Poverty. 2017 Mar 22;6(1):63. (PMID: 28327187)
Parasitology. 2014 Dec;141(14):1841-55. (PMID: 24932595)
PLoS Negl Trop Dis. 2014 Nov 20;8(11):e3286. (PMID: 25412105)
Curr Opin Infect Dis. 2008 Dec;21(6):659-67. (PMID: 18978535)
PLoS Negl Trop Dis. 2017 Feb 17;11(2):e0005372. (PMID: 28212414)
Int J Epidemiol. 2015 Feb;44(1):87-97. (PMID: 25433704)
Lancet. 2014 Jun 28;383(9936):2253-64. (PMID: 24698483)
Parasit Vectors. 2018 Feb 23;11(1):111. (PMID: 29475457)
Front Immunol. 2019 Apr 04;10:682. (PMID: 31019510)
Expert Rev Anti Infect Ther. 2013 Nov;11(11):1237-58. (PMID: 24127662)
Parasit Vectors. 2018 Oct 23;11(1):552. (PMID: 30352631)
Exp Parasitol. 1986 Jun;61(3):294-303. (PMID: 3086114)
Infect Dis Poverty. 2017 Jun 16;6(1):110. (PMID: 28622767)
mBio. 2016 Aug 09;7(4):. (PMID: 27507822)
Trans R Soc Trop Med Hyg. 2004 Jan;98(1):18-27. (PMID: 14702835)
BMC Infect Dis. 2018 Dec 14;18(1):662. (PMID: 30547750)
Am J Trop Med Hyg. 2016 Feb;94(2):361-4. (PMID: 26556831)
Parasitology. 2001 May;122(Pt 5):537-44. (PMID: 11393827)
Am J Trop Med Hyg. 2013 Jul;89(1):46-50. (PMID: 23716406)
PLoS Negl Trop Dis. 2013;7(3):e2109. (PMID: 23556011)
PLoS Negl Trop Dis. 2018 Dec 14;12(12):e0006941. (PMID: 30550594)
Parasite Immunol. 2014 Aug;36(8):347-57. (PMID: 25142505)
Nat Rev Dis Primers. 2018 Aug 9;4(1):13. (PMID: 30093684)
Front Public Health. 2015 Mar 19;3:48. (PMID: 25853117)
PLoS Negl Trop Dis. 2014 Sep 11;8(9):e3139. (PMID: 25211217)
Am J Trop Med Hyg. 2013 Mar;88(3):426-432. (PMID: 23339198)
Am J Trop Med Hyg. 2016 Mar;94(3):605-610. (PMID: 26755565)
J Biomed Inform. 2019 Jul;95:103208. (PMID: 31078660)
J Infect Dis. 2014 Dec 15;210(12):2009-16. (PMID: 25001462)
Am J Trop Med Hyg. 1996 Apr;54(4):319-24. (PMID: 8615440)
PLoS Negl Trop Dis. 2015 Feb 19;9(2):e0003504. (PMID: 25695740)
Acta Trop. 2019 Nov;199:105150. (PMID: 31425672)
Biomed Res Int. 2017;2017:7035025. (PMID: 29094048)
Am J Trop Med Hyg. 2019 Mar;100(3):578-583. (PMID: 30608053)
J Infect Dis. 1999 Apr;179(4):996-1003. (PMID: 10068597)
Int J Parasitol. 2005 Nov;35(13):1453-7. (PMID: 16002073)

ClinicalTrials.gov NCT02868385

0 (Anthelmintics)
0 (Antigens, Helminth)
0 (CCA protein, Schistosoma mansoni)
0 (Glycoproteins)
0 (Helminth Proteins)
6490C9U457 (Praziquantel)

Date Created: 20200321 Date Completed: 20200513 Latest Revision: 20200513

20240829

PMC7112237

10.1371/journal.pntd.0008189

32196506